BRIEF-Pharming and Salix say FDA extended PDUFA date for angioedema drug Ruconest

AMSTERDAM Mon Feb 24, 2014 1:09am EST

AMSTERDAM Feb 24 (Reuters) - Pharming Group NV : * FDA extends prescription drug user fee act date for co's biologics license

application for drug Ruconest * FDA extends date to July 16, 2014 * Cos U.S. marketing approval of Ruconest that treats acute angioedema attacks in patients with hereditary angioedema